Introduction: Immune checkpoint inhibitors (ICI) are associated with a wide spectrum of
neurologic immune-related adverse events (irAEs) including meningo-encephalitis …

Autoimmune neuromuscular junction disorders are rare. However, myasthenia gravis is
being increasingly recognised in people older than 50 years. In the past 5–10 years …

Objective This study aimed to explore the relationship between systemic inflammation
markers and clinical activity, respiratory failure, and prognosis in patients with myasthenia …

Introduction Myasthenia gravis is a long-lasting autoimmune neuromuscular disease caused
by antibodies attacking the neuromuscular junction, which can result in muscle weakness …

Abstract Coronavirus disease 2019 (COVID-19), a disease caused by the novel
betacoronavirus (SARS-CoV-2) has become a global pandemic threat. COVID-19 caused by …

Background Myasthenia gravis (MG) can have a variety of respiratory presentations, ranging
from mild symptoms through to respiratory failure. The evaluation of respiratory function in …

Introduction Myasthenia gravis is characterized by fluctuating muscle weakness that
improves with rest and worsens with effort or throughout the day. Areas Covered …

Introduction Several novel cancer therapies have been developed, many of which focused
on immune system modulation. These include immune checkpoint inhibitors, modulators, T …

The use of non-invasive respiratory strategies (NIRS) is crucial to improve oxygenation in
COVID-19 patients with hypoxemia refractory to conventional oxygen therapy. However, the …

Introduction Myasthenia gravis is a rare and chronic autoimmune disease. The study aimed
to evaluate the influence of symptom severity and fatigue on sleep quality in patients with …